Evidence map›Paper›PMID 42898634›Full record

ReviewFrontiers in immunology2026

The role of microbiota on thyroid cancer: from carcinogenicity, treatment and predictability.

Jian-Li Han, Xin-da Lu, Jia-Jia Du

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jian-Li HanShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Xin-da LuThird Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Jia-Jia DuShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, more and more attention has been paid to the mechanism of microbiota in thyroid cancer (TC). Gut microbiota (GM) and its metabolites can regulate the immune system and affect thyroid function through the gut-thyroid axis. When the GM is dysregulated, the intestinal barrier function is impaired, resulting in immune dysfunction, chronic inflammation, oncogene activation, and eventually leading to the occurrence of TC. In addition, intratumoral microbiota (ITM) is also directly involved in the occurrence, progression and invasion of TC. However, the mechanism of action between the microbiome and TC is still under exploration, and the research results in this field will have a major impact on disease cognition and clinical intervention. Chemotherapy, radiation, and immunotherapy are the main non-surgical treatments for TC. Furthermore, gut microbiota modulators, including probiotics and prebiotics, represent a potential therapeutic strategy for TC, offering new avenues for individualized treatment. In addition, the differences of microbiota in patients with TC can be used to predict tumor subtype, invasion, lymph node metastasis, and the efficacy of

Indexed as

Gastrointestinal MicrobiomeThyroid NeoplasmsAnimalsCarcinogenesisHumansPrebioticsProbioticsPrebioticsgut-thyroid axisimmunomodulationmicrobiotaradioiodine therapythyroid cancer

Identifiers

PMID42898634
PMCPMC13678434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.